211 related articles for article (PubMed ID: 23628473)
1. The PPARα agonist fenofibrate suppresses B-cell lymphoma in mice by modulating lipid metabolism.
Huang J; Das SK; Jha P; Al Zoughbi W; Schauer S; Claudel T; Sexl V; Vesely P; Birner-Gruenberger R; Kratky D; Trauner M; Hoefler G
Biochim Biophys Acta; 2013 Oct; 1831(10):1555-65. PubMed ID: 23628473
[TBL] [Abstract][Full Text] [Related]
2. Peroxisome proliferator-activated receptor-alpha gene level differently affects lipid metabolism and inflammation in apolipoprotein E2 knock-in mice.
Lalloyer F; Wouters K; Baron M; Caron S; Vallez E; Vanhoutte J; Baugé E; Shiri-Sverdlov R; Hofker M; Staels B; Tailleux A
Arterioscler Thromb Vasc Biol; 2011 Jul; 31(7):1573-9. PubMed ID: 21474829
[TBL] [Abstract][Full Text] [Related]
3. Selective peroxisome proliferator-activated receptor-α modulator K-877 efficiently activates the peroxisome proliferator-activated receptor-α pathway and improves lipid metabolism in mice.
Takei K; Han SI; Murayama Y; Satoh A; Oikawa F; Ohno H; Osaki Y; Matsuzaka T; Sekiya M; Iwasaki H; Yatoh S; Yahagi N; Suzuki H; Yamada N; Nakagawa Y; Shimano H
J Diabetes Investig; 2017 Jul; 8(4):446-452. PubMed ID: 28084058
[TBL] [Abstract][Full Text] [Related]
4. Dietary isoflavone supplementation modulates lipid metabolism via PPARalpha-dependent and -independent mechanisms.
Mezei O; Li Y; Mullen E; Ross-Viola JS; Shay NF
Physiol Genomics; 2006 Jun; 26(1):8-14. PubMed ID: 16507786
[TBL] [Abstract][Full Text] [Related]
5. Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome.
Belfort R; Berria R; Cornell J; Cusi K
J Clin Endocrinol Metab; 2010 Feb; 95(2):829-36. PubMed ID: 20061429
[TBL] [Abstract][Full Text] [Related]
6. PPARα/γ agonists and antagonists differently affect hepatic lipid metabolism, oxidative stress and inflammatory cytokine production in steatohepatitic rats.
Zhang Y; Cui Y; Wang XL; Shang X; Qi ZG; Xue J; Zhao X; Deng M; Xie ML
Cytokine; 2015 Sep; 75(1):127-35. PubMed ID: 26194065
[TBL] [Abstract][Full Text] [Related]
7. Peroxisome proliferator-activated receptor-alpha selective ligand reduces adiposity, improves insulin sensitivity and inhibits atherosclerosis in LDL receptor-deficient mice.
Srivastava RA; Jahagirdar R; Azhar S; Sharma S; Bisgaier CL
Mol Cell Biochem; 2006 Apr; 285(1-2):35-50. PubMed ID: 16477380
[TBL] [Abstract][Full Text] [Related]
8. Fenofibrate lowers lipid accumulation in myotubes by modulating the PPARα/AMPK/FoxO1/ATGL pathway.
Chen WL; Chen YL; Chiang YM; Wang SG; Lee HM
Biochem Pharmacol; 2012 Aug; 84(4):522-31. PubMed ID: 22687626
[TBL] [Abstract][Full Text] [Related]
9. Hepatic
Lee YH; Jang HJ; Kim S; Choi SS; Khim KW; Eom HJ; Hyun J; Shin KJ; Chae YC; Kim H; Park J; Park NH; Woo CY; Hong CH; Koh EH; Nam D; Choi JH
Elife; 2021 Dec; 10():. PubMed ID: 34964438
[TBL] [Abstract][Full Text] [Related]
10. Peroxisome proliferator-activated receptor α activation induces hepatic steatosis, suggesting an adverse effect.
Yan F; Wang Q; Xu C; Cao M; Zhou X; Wang T; Yu C; Jing F; Chen W; Gao L; Zhao J
PLoS One; 2014; 9(6):e99245. PubMed ID: 24926685
[TBL] [Abstract][Full Text] [Related]
11. Fenofibrate prevents obesity and hypertriglyceridemia in low-density lipoprotein receptor-null mice.
Jeong S; Kim M; Han M; Lee H; Ahn J; Kim M; Song YH; Shin C; Nam KH; Kim TW; Oh GT; Yoon M
Metabolism; 2004 May; 53(5):607-13. PubMed ID: 15131765
[TBL] [Abstract][Full Text] [Related]
12. Fenofibrate simultaneously induces hepatic fatty acid oxidation, synthesis, and elongation in mice.
Oosterveer MH; Grefhorst A; van Dijk TH; Havinga R; Staels B; Kuipers F; Groen AK; Reijngoud DJ
J Biol Chem; 2009 Dec; 284(49):34036-44. PubMed ID: 19801551
[TBL] [Abstract][Full Text] [Related]
13. Fenofibrate, a PPARα agonist, reduces hepatic fat accumulation through the upregulation of TFEB-mediated lipophagy.
Yoo J; Jeong IK; Ahn KJ; Chung HY; Hwang YC
Metabolism; 2021 Jul; 120():154798. PubMed ID: 33984335
[TBL] [Abstract][Full Text] [Related]
14. Activation of peroxisome proliferator-activated receptor-alpha in mice induces expression of the hepatic low-density lipoprotein receptor.
Huang Z; Zhou X; Nicholson AC; Gotto AM; Hajjar DP; Han J
Br J Pharmacol; 2008 Oct; 155(4):596-605. PubMed ID: 18852694
[TBL] [Abstract][Full Text] [Related]
15. The effects of herbal composition Gambigyeongsinhwan (4) on hepatic steatosis and inflammation in Otsuka Long-Evans Tokushima fatty rats and HepG2 cells.
Yoon S; Kim J; Lee H; Lee H; Lim J; Yang H; Shin SS; Yoon M
J Ethnopharmacol; 2017 Jan; 195():204-213. PubMed ID: 27845265
[TBL] [Abstract][Full Text] [Related]
16. Effects of fenofibrate on high-fat diet-induced body weight gain and adiposity in female C57BL/6J mice.
Jeong S; Han M; Lee H; Kim M; Kim J; Nicol CJ; Kim BH; Choi JH; Nam KH; Oh GT; Yoon M
Metabolism; 2004 Oct; 53(10):1284-9. PubMed ID: 15375783
[TBL] [Abstract][Full Text] [Related]
17. Fish oil and fenofibrate prevented phosphorylation-dependent hepatic sortilin 1 degradation in Western diet-fed mice.
Li J; Bi L; Hulke M; Li T
J Biol Chem; 2014 Aug; 289(32):22437-49. PubMed ID: 24986865
[TBL] [Abstract][Full Text] [Related]
18. Kaempferol regulates the lipid-profile in high-fat diet-fed rats through an increase in hepatic PPARα levels.
Chang CJ; Tzeng TF; Liou SS; Chang YS; Liu IM
Planta Med; 2011 Nov; 77(17):1876-82. PubMed ID: 21728151
[TBL] [Abstract][Full Text] [Related]
19. The hepatokine FGF21 is crucial for peroxisome proliferator-activated receptor-α agonist-induced amelioration of metabolic disorders in obese mice.
Goto T; Hirata M; Aoki Y; Iwase M; Takahashi H; Kim M; Li Y; Jheng HF; Nomura W; Takahashi N; Kim CS; Yu R; Seno S; Matsuda H; Aizawa-Abe M; Ebihara K; Itoh N; Kawada T
J Biol Chem; 2017 Jun; 292(22):9175-9190. PubMed ID: 28404815
[TBL] [Abstract][Full Text] [Related]
20. Antiepileptic Drug-Activated Constitutive Androstane Receptor Inhibits Peroxisome Proliferator-Activated Receptor
Shizu R; Otsuka Y; Ezaki K; Ishii C; Arakawa S; Amaike Y; Abe T; Hosaka T; Sasaki T; Kanno Y; Miyata M; Yamazoe Y; Yoshinari K
Mol Pharmacol; 2020 Nov; 98(5):634-647. PubMed ID: 32892155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
